Orally administrable anti-metastatic lectin compositions and met

Details Orally administrable anti-metastatic lectin compositions and met Orally administrable anti-metastatic lectin compositions and met

1990-05-23

1991-10-01

Nutter, Nathan M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

4241951, 530396, A01N 3718, A61K 3702, A61K 3578

Patent

active

050533860

ABSTRACT:
Compositions and methods of treatment comprising the lectins Abrin and Abrus agglutinin for the suppression of post-surgical malignant tumor metastasis are disclosed. Also disclosed is the administration of compositions and methods of treatment utilizing the above lectins in combination with either or both radiation treatment and/or chemotherapy.

REFERENCES:
Dyer "An Index of Tumor Chemotherapy" National Cancer Institute, NIH, Mar. 1949, p. 175.
Chabner, et al. "Clinical Pharmacology of Cancer Chemotherapy" taken from Chapter 9 of Cancer, Principles and Practice of Oncology, Lippincott Co., Philadelphia, 1982, pp. 158-159.
Tung, T. C. et al., J. Chinese Oncol. Soc., 3(3) 1-8 (1987), Inhibitory Effect by Orally Administered Abrus Agglutinin on the Anti-Metastasis of Sarcoma-180 and B-16 Melanoma.

Affiliated with

Also associated with

Rating

Orally administrable anti-metastatic lectin compositions and met does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Orally administrable anti-metastatic lectin compositions and met, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administrable anti-metastatic lectin compositions and met will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1755047